Arovella Therapeutics (ALA) Q1 2027 TU earnings summary

Executive summary

• Released two clinical batches of ALA-101, activated The Alfred and Epworth Hospital trial sites, and began screening patients; first dosing was expected in October 2026.

• Quarter-end cash was $11.6 million; after the $4.03 million FY26 R&D tax incentive rebate received in October, pro forma cash was approximately $15.63 million before subsequent cash movements.

• Priorities are obtaining preliminary safety and efficacy data for ALA-101 and advancing the ALA-105 solid-tumour program towards the clinic.

Financial highlights

• Net operating cash outflow was $2.732 million for the quarter; R&D and staff costs represented 89% of operating outflows.

• Cash and cash equivalents declined from $14.353 million at quarter start to $11.602 million at quarter end; exchange-rate movements reduced cash by $19,000.

• Operating cash flows included $1.720 million for R&D, $825,000 for staff, $304,000 for administration and corporate costs, and $143,000 of interest received.

Outlook and guidance

• First ALA-101 patient dosing was expected in October 2026; by end Q1 CY27, the target was to complete first-dose-level dosing, begin the second level, and accelerate enrolment.

• Early ALA-101 data are expected to assess safety, tolerability, expansion and persistence, CD19-positive B-cell depletion, and preliminary antitumour activity.

• Near-term milestones include completing ALA-105 in vivo efficacy studies, preparing regulatory filings for ALA-101 autoimmune-disease expansion, and starting ALA-105 IND-enabling non-clinical and manufacturing work.

• Two additional ALA-101 trial sites were being activated; further sites were expected to follow initial safety data.